SUBSCRIBE
SUBSCRIBE
News   FDA

Progenics Pharmaceuticals, Inc., Wyeth Say Bowel Drug Gets Canadian OK

April 1, 2008 | 
1 min read
April 1 (Reuters) - Progenics Pharmaceuticals Inc and partner Wyeth said their bowel drug, Relistor, received marketing clearance from Canadian authorities, sending Progenics' shares up 7 percent before the bell.
FDA Approvals
MORE ON THIS TOPIC
FDA signage at its headquarters in Maryland
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Regulatory
In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements
December 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Red round circle with a pause button or icon against yellow background.
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
December 5, 2025
 · 
2 min read
 · 
Tristan Manalac